RELEASE: Signature Discovery Accelerates Global Growth With Major North American Acquisition

NOTTINGHAM, England, Aug.

RELEASE: Signature Discovery Accelerates Global Growth With Major North American Acquisition

NOTTINGHAM, England, Aug. 1, 2023 /PRNewswire/ -- Leading integrated drug discovery partner, Sygnature Discovery ("Sygnature"), has announced the acquisition of one of the largest discovery contract research organizations in America of the North, Canada-based NuChem Sciences. This acquisition solidifies Sygnature as one of the world's largest developers of integrated drug discovery phase solutions and advances its vision to become the global market leader.

The transaction creates a significant competitive advantage for Syngnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market. Together, Sygnature Discovery and NuChem are creating a global force offering drug discovery expertise to support client programs from target validation to candidate selection, combining the best of North American and UK operations. .

Marc Lebel, P.D., President and CEO of NuChem Sciences, said, "Our company's goals and values ​​align perfectly with those of Signature to become a global leader in drug discovery services. We are delighted to become an integral part of of the Signature Group, allowing us to leverage our deep scientific expertise and presence in North America and Europe, to the benefit of customers and employees."

NuChem Sciences, a leading discovery CRO in the North American market, employs more than 300 people in centers of excellence in Montreal and Quebec City, Canada, where the company will continue to operate and drive further market expansion in the Americas. from North.

Founded in 2011, NuChem Sciences offers expert independent and integrated discovery solutions in medicinal, synthetic, scale-up, process, and computational chemistry, as well as DMPK, in vitro biology, and in vivo pharmacology. In addition, the company provides protein chemistry services and offers crucial knowledge-based expertise in structural biology in the early stages of drug discovery for global pharmaceutical and biotech companies.

Following this acquisition, Sygnature Discovery will have more than 1,000 employees of 53 nationalities, including more than 900 scientists working on independent and integrated drug discovery programs for the pharmaceutical, biotech, venture capital and NFP industries. Founded in 2004, the company has successfully delivered more than 40 new drug candidates in preclinical development and 22 in clinical trials, with its scientists named on more than 170 patent applications.

Dr. Simon Hirst, CEO of Sygnature Discovery, commented: "This acquisition represents a critical milestone in Sygnature's growth plan, enabling us to deliver better discovery solutions to customers around the world. The addition of NuChem Sciences enhances largely the offering of Sygnature Discovery, making us a highly differentiated and integrated drug discovery partner with unmatched scale and reach NuChem is a like-minded company that complements existing Sygnature services, towards our mission joint effort to improve the health of the world.

In addition, Marc Lebel commented that "this acquisition could not have been made without the support and collaboration of Amorchem, Investissement Québec, Fonds de solidarité FTQ and Business Development Bank of Canada; I would like to extend my thanks to all involved."

This is the third in a series of acquisitions in the last sixteen months that have formed part of Sygnature's global expansion, following the investment from Five Arrows in the summer of 2021. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

Acerca de Signature Discovery

Sygnature Discovery is a world-leading UK-based integrated drug discovery contract research organization with headquarters in Nottingham and additional facilities in Alderley Park, Macclesfield and Glasgow. Its staff of more than 1,000, including 900 scientists, partners with global pharmaceutical, biotech and NFP organizations.

Since 2004, Syngnature Discovery has delivered more than 40 new preclinical and 22 clinical compounds, with its scientists named on more than 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.

About NuChem Sciences

NuChem Sciences, which employs 300 scientists and support staff, is headquartered in Montreal, Quebec, and offers a range of independent and integrated discovery services in chemistry, biochemistry, in vitro biology, DMPK, structural biology, and in vivo pharmacology.

About Five Arrows

Five Arrows is the alternative asset arm of the Rothschild

Photo - -

View original content: